Pharmaceutical Filtration Market Report 2025

The pharmaceutical filtration market size has grown strongly in recent years. It will grow from $7.29 billion in 2024 to $7.72 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to stringent regulatory standards, focus on drug purity and safety, increased in prevalence of chronic diseases, focus on cost-efficiency.

The pharmaceutical filtration market size is expected to see strong growth in the next few years. It will grow to $9.71 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rapid growth in personalized medicine, increasing emphasis on continuous manufacturing, global outbreaks and vaccine production, demand for aseptic processing, global expansion of pharmaceutical markets. Major trends in the forecast period include rising adoption of single-use filtration technologies, growing demand for sterilizing filtration, advancements in membrane filtration, focus on virus filtration for bioprocessing, integration of filtration into single-use systems, focus on pre-filtration steps.

An increase in the demand for generic drugs is anticipated to boost the growth of the pharmaceutical filtration market in the future. Generic pharmaceuticals are designed to be identical to existing approved brand-name drugs. Pharmaceutical filtration is utilized in the production of generic drugs by removing solid particulate matter from a fluid, which can be either a liquid or a gas, using a porous medium. For example, in September 2024, the India Brand Equity Foundation, an export promotion agency based in India, reported that India is the world's largest supplier of generic drugs. As of June 2022, the Indian pharmaceutical sector provides over 40% of the generic drug demand in the United States and 25% of all pharmaceuticals in the United Kingdom. Thus, the rising demand for generic drugs is significantly driving the growth of the pharmaceutical filtration market.

The growing prevalence of chronic diseases is projected to accelerate the growth of the pharmaceutical filtration market in the upcoming years. Chronic diseases are medical conditions that persist for an extended period, typically three months or more, and cannot be prevented or treated with immunizations, nor do they simply resolve on their own. The global rise in chronic illnesses has resulted in the development of medications to treat these conditions, necessitating effective filtration methods to ensure product quality. For instance, in March 2022, the Australian Bureau of Statistics, a self-contained constitutional organization responsible for data collection and analysis and providing evidence-based recommendations to federal, state, and territorial governments, reported that more than three-quarters (78.6%) of Australians had at least one long-term health issue. Nearly half of the population (46.6%, or 11.6 million individuals) suffered from at least one chronic illness. Consequently, the increasing prevalence of chronic diseases is propelling the pharmaceutical filtration market.

Product innovation is a significant trend gaining traction in the pharmaceutical filtration market. Key players in this sector are developing new products featuring advanced filtration methods, such as high-volume filtration plates, to strengthen their market presence. For instance, in September 2023, Sartorius, a Germany-based supplier of pharmaceutical and laboratory equipment, launched the Sartoflow 450, an innovative filtration system tailored for the biopharmaceutical industry. This advanced system offers enhanced contamination control through improved filter design and reduced operational downtime. The Sartoflow 450 is specifically engineered to optimize filtration processes for cell cultures, vaccines, and other biologics, greatly minimizing the risk of contamination and ensuring product integrity.

Leading companies in the pharmaceutical filtration market are adopting a strategic partnership approach to enhance downstream purification processes for exosome production. These strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in January 2023, RoosterBio Inc., a U.S.-based biopharmaceutical company, announced a strategic collaboration with Sartorius AG, a Germany-based pharmaceutical and laboratory equipment provider. This partnership aims to deliver exceptional expertise and solutions for an exosome manufacturing platform utilizing human mesenchymal stem/stromal cells (hMSCs). The goal is to achieve industry-leading potency, purity, and yield. The collaboration will primarily focus on developing comprehensive analytical methods for characterizing exosomes and other extracellular vesicles (EVs), facilitating the establishment of quantitative quality control strategies for both exosome purification intermediates and the final drug product. Additionally, the partnership will offer scalable filtration equipment, such as Sartoflow Smart and Sartoflow Advanced, to enhance clarity, concentration, and formulation.

In May 2023, Xylem Inc., a U.S.-based water technology provider, completed the acquisition of Evoqua Water Technologies for $7.5 billion. This acquisition enables Xylem to more effectively address the growing demand for sustainable water solutions while bolstering its operational capabilities and market presence. Evoqua Water Technologies specializes in providing pharmaceutical filtration solutions.

Major companies operating in the pharmaceutical filtration market are 3M Health Care, Danaher Corporation, Amazon Filters Ltd., Eaton Corporation PLC, GE Healthcare, Graver Technologies LLC, Meissner Filtration Products, Merck & Co. Inc., Parker Bioscience Filtration, Sartorius AG, Repligen, Porvair PLC, Alfa Laval AB, Corning Incorporated, Thermo Fisher Scientific, Freudenberg Group, Avantor Inc., Berry Global Inc., Cantel Medical Corp., Cole-Parmer Instrument Company LLC., Donaldson Company Inc., Entegris Inc., Filtration Group Corporation, Synder Filtration Inc, GVS S.p.A., Koch Membrane Systems Inc., Lenntech B.V., Mann+Hummel Group, Membrane Solutions, Pall Corporation.

North America was the largest region in the pharmaceutical filtration market in 2024. The regions covered in the pharmaceutical filtration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical filtration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pharmaceutical filtration serves as a method for eliminating solid particulate matter from fluids, whether they are liquids or gases, by utilizing a porous medium. This technique is widely applied in pharmaceutical production to eliminate contaminants like particulate matter and bacteria from solids, air, liquids, and gases.

The primary products within pharmaceutical filtration encompass membrane filters, prefilters, depth media, single-use systems, cartridges and capsules, filter holders, and filtration accessories. Membrane filters allow the flow of fluids or gases while obstructing the passage of particles and microorganisms. Techniques like microfiltration, ultrafiltration, crossflow filtration, and nanofiltration are employed across various operational scales including manufacturing, pilot studies, and research and development. These filtration methods find application in final product processing, raw material filtration, bioburden testing, cell separation, water purification, and air purification.

The pharmaceutical filtration market research report is one of a series of new reports that provides pharmaceutical filtration market statistics, including pharmaceutical filtration industry global market size, regional shares, competitors with a pharmaceutical filtration market share, detailed pharmaceutical filtration market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical filtration industry. This pharmaceutical filtration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical filtration market includes revenues earned by entities by providing reverse osmosis, sterile filtration, chromatography, sterile sampling and nanofiltration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.